KEY TAKEAWAYS
- The study aimed to assess the prevalence of grade ≥2 dermatitis and associated risk factors in adjuvant RT for BC patients.
- Researchers identified that the prevalence of grade ≥2 dermatitis and independent risk factors during BC RT are crucial for improving patient care and trial design.
Patients undergoing adjuvant radiotherapy (RT) for breast cancer (BC) often face the challenge of grade ≥2 dermatitis. In the HeAT project, a mobile application (app) is being tested to reduce radiation dermatitis.
Dirk Rades and the team aimed to pinpoint the prevalence of grade ≥2 dermatitis and its associated risk factors, which is essential for shaping the upcoming trial.
They performed an inclusive analysis of 327 patients with BC who underwent irradiation between 2022 and 2023. The study investigated the prevalence of grade ≥2 dermatitis and examined 23 potential risk factors associated with its development.
About 31.2% of patients experienced grade ≥2 dermatitis during the study period. Multivariate analysis revealed significant associations between grade ≥2 dermatitis and chronic inflammatory disease (P=0.001), significant cardiovascular disease (P<0.001), smoking history >10 pack years (P<0.001), advanced T-stage (P=0.017), normo-fractionation (P<0.001), and radiation boost (P<0.001).
The study concluded that identifying the prevalence of grade ≥2 dermatitis and independent risk factors during adjuvant RT for invasive BC is essential for enhancing patient care and informing the design of a prospective trial.
Source: https://pubmed.ncbi.nlm.nih.gov/38537981/
Rades D, Kristiansen C, Timke C, et al. (2024). “Clinically Significant Dermatitis During Adjuvant Radiotherapy for Invasive Breast Cancer.” Anticancer Res. 2024 Apr;44(4):1525-1531. doi: 10.21873/anticanres.16949. PMID: 38537981.
